Important Notice: Opine Online provides an
informal way for the research community to express its views on current topics.
The results are not a scientific poll and do not necessarily reflect the percentages
of all Alzheimer researchers who agree with these positions.
Poll Question: Marijuana for AD treatment: Junkie science or worth sniffing out?
Will encourage pot-smoking. Just say No.
Intriguing science. Needs more $$s.
Not in the U.S. Regulations, politics and prejudice are too hard to overcome.
Risks outweigh benefits. No.
A synthetic cannabinoid receptor agonist is the way to go
If hash brownies can make grandma lucid, no one will invest in research
Cannabinoid receptor agonists are effective at preventing amyloid-β toxicity (Milton 2002; Milton 2005). But at higher doses, they can have toxic effects themselves, and as a treatment, an effective dosing regimen is essential.
A specific agonist without toxic or detrimental behavioral actions would be the ideal candidate; more investment may help develop such a compound.
The future for cannabinoid therapy still needs investment to realize its true potential.
References: Milton NG. Phosphorylated amyloid-beta: the toxic intermediate in alzheimer's disease neurodegeneration. Subcell Biochem. 2005;38:381-402. Review. Abstract
Milton NG. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett. 2002 Oct 31;332(2):127-30. Abstract